Literature DB >> 3297437

Natural killer cell activity and antibody-dependent cellular cytotoxicity in patients under various immunosuppressive regimens.

C Müller, G Schernthaner, J Kovarik, W Kalinowska, C C Zielinski.   

Abstract

The influence of various modes of immunosuppression using cyclosporin A (CyA), corticosteroids (Cort), azathioprine (AZA), and antithymocyte globulin (ATG) alone or in combination with each other upon natural killer (NK) cell activity and antibody-dependent cellular cytotoxicity (ADCC) was assessed. CyA given alone did not influence either NK or ADCC activity; in contrast, the administration of Cort resulted in a significant decline (P less than 0.01) of ADCC but not of NK activity (P greater than 0.1). The combination of the two drugs led to a significant impairment of NK activity (P less than 0.01). The combination of AZA and Cort was found to produce an even more pronounced reduction in NK activity compared to both healthy controls (P less than 0.001) as well as patients from the CyA + Cort group (P less than 0.001). A similar decrease was found also after the addition of ATG to CyA + Cort (P less than 0.001, compared both with patients on CyA + Cort and with controls). In these instances, ADCC showed an overall similar pattern. We conclude that the administration of either CyA or Cort does not influence NK activity, while the combination of CyA with Cort and of AZA with Cort leads to a decrease in both NK and ADCC activities. The monotherapy with Cort only leads to a reduction of ADCC. These findings may explain the higher incidence of malignancies in patients undergoing combined immunosuppressive treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297437     DOI: 10.1016/0090-1229(87)90047-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  7 in total

1.  Effects of in vivo treatment with FK506 on natural killer cells in rats.

Authors:  P M Markus; M R Van den Brink; B A Luchs; J J Fung; T E Starzl; J C Hiserodt
Journal:  Transplantation       Date:  1991-04       Impact factor: 4.939

2.  Natural killer cell activity during measles.

Authors:  D E Griffin; B J Ward; E Jauregui; R T Johnson; A Vaisberg
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

3.  Circulating NK cells and their subsets in Behçet's disease.

Authors:  M S Hasan; P L Ryan; L A Bergmeier; F Fortune
Journal:  Clin Exp Immunol       Date:  2017-03-13       Impact factor: 4.330

4.  Small-Molecule Immunosuppressive Drugs and Therapeutic Immunoglobulins Differentially Inhibit NK Cell Effector Functions in vitro.

Authors:  Amandine Pradier; Maria Papaserafeim; Ning Li; Anke Rietveld; Charlotte Kaestel; Lyssia Gruaz; Cédric Vonarburg; Rolf Spirig; Gisella L Puga Yung; Jörg D Seebach
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

5.  Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.

Authors:  Heiner Zimmermann; Theresa Weiland; Jamie P Nourse; Maher K Gandhi; Petra Reinke; Ruth Neuhaus; Mohsen Karbasiyan; Barbara Gärtner; Ioannis Anagnostopoulos; Hanno Riess; Ralf U Trappe; Stephan Oertel
Journal:  J Immunol Res       Date:  2014-02-10       Impact factor: 4.818

6.  Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes.

Authors:  S Yano; S Sone; Y Nishioka; M Naito; T Tsuruo; T Ogura
Journal:  Jpn J Cancer Res       Date:  1994-02

7.  Cytotoxicity of Donor Natural Killer Cells to Allo-Reactive T Cells Are Related With Acute Graft-vs.-Host-Disease Following Allogeneic Stem Cell Transplantation.

Authors:  Lixia Sheng; Qitian Mu; Xiaoqing Wu; Shujun Yang; Huiling Zhu; Jiaping Wang; Yanli Lai; Hao Wu; Ye Sun; Yongxian Hu; Huarui Fu; Yi Wang; Kaihong Xu; Yongcheng Sun; Yanli Zhang; Ping Zhang; Miao Zhou; Binbin Lai; Zhijuan Xu; Minjie Gao; Yi Zhang; Guifang Ouyang
Journal:  Front Immunol       Date:  2020-07-31       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.